Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy

► NAT2, CYP2E1 and GSTM1/GSTT1 variants influence safety of anti-tuberculosis therapy. ► NAT2*5/*5 carriers have increased susceptibility to mild elevation in liver enzymes. ► CYP2E1 and GSTM1/GSTT1 are common variants that are related to increased liver biomarkers. ► CYP2E1 inhibitors increase the susceptibility to increased liver biomarkers in TB.